Top

Published in:

01-03-2024 | Infliximab | Case report

Infliximab/steroids/vedolizumab

Pulmonary histoplasmosis, rebound effect in the form of worsening Crohn's disease and lack of efficacy

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

…

Country of occurrence, reporter country and primary source country not stated.

Chokshi A, et al. PULMONARY HISTOPLASMOSIS IN A PATIENT WITH CROHN'S DISEASE ON ANTI-TNF INHIBITOR THERAPY. Gastroenterology 166 (Suppl.): S1-S2, No. 3, Feb 2024. Available from: URL: https://dx.doi.org/10.1053/j.gastro.2023.11.025 [abstract]

Title: Infliximab/steroids/vedolizumab
Pulmonary histoplasmosis, rebound effect in the form of worsening Crohn's disease and lack of efficacy
Publication date: 01-03-2024
Publisher: Springer International Publishing
Keywords: Infliximab
Crohn's Disease
Histoplasmosis
Colonoscopy
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-54512-3